Loading...

Eisai Co., Ltd.

ESALY•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$61.51
$-1.33(-2.11%)

Eisai Co., Ltd. (ESALY) Stock Overview

Explore Eisai Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 68.2/100

Key Financials

Market Cap17.6B
P/E Ratio55.82
EPS (TTM)$3.00
ROE0.06%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$110.97

ESALY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Eisai Co., Ltd. (ESALY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $110.97.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 55.82 and a market capitalization of 17.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ESALYStats details for ESALY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ESALYAnalyst Recommendations details for ESALY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

CEO

Mr. Haruo Naito

Employees

11,092

Headquarters

4-6-10, Koishikawa, Tokyo

Founded

1995

Frequently Asked Questions

;